P Vandel

Summary

Affiliation: CHU Jean Minjoz
Country: France

Publications

  1. ncbi Antidepressant drugs in the elderly--role of the cytochrome P450 2D6
    Pierre Vandel
    Service de Psychiatrie et Psychologie médicale, Besancon, France
    World J Biol Psychiatry 4:74-80. 2003
  2. ncbi Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients
    P Vandel
    Fédération de Psychiatrie et Psychologie Médicale, Centre Hospitalo Universitaire, 25030 Besancon, France
    Hum Psychopharmacol 19:293-8. 2004
  3. ncbi Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism
    P Vandel
    Service de Psychiatrie et Psychologie médicale, CHU 25030 Besançon, France
    Curr Pharm Des 13:241-50. 2007
  4. ncbi Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
    P Vandel
    Hospitalo University Department of Psychiatry and Medical Psychology, Centre Hospitalo Universitaire, Besancon, France
    Eur J Clin Pharmacol 55:659-65. 1999
  5. ncbi Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study
    Lina Steinacher
    Praxis am Zweierplatz, Badenerstrasse 67, CH-8004 Zurich, Switzerland
    Eur Neuropsychopharmacol 12:255-60. 2002
  6. ncbi A comparative study of milnacipran and paroxetine in outpatients with major depression
    Daniel Sechter
    Service de psychiatrie de l adulte, Centre Hospitalier Universitaire St Jacques, Besancon, Cedex F 25030, France
    J Affect Disord 83:233-6. 2004
  7. ncbi Odor perception in patients with mood disorders
    Sandrine Lombion-Pouthier
    Laboratoire de Neurosciences, Place Leclerc, , , France
    J Affect Disord 90:187-91. 2006

Collaborators

  • C B Eap
  • P Baumann
  • D Zullino
  • Sandrine Lombion-Pouthier
  • Daniel Sechter
  • Lina Steinacher
  • Sylvie Nezelof
  • Jean-Louis Millot
  • Emannuel Haffen
  • Alain Tournoux
  • Fabienne Cabanac
  • Emmanuel Weiller
  • Nicole Pezous
  • Marlyse Brawand-Amey

Detail Information

Publications7

  1. ncbi Antidepressant drugs in the elderly--role of the cytochrome P450 2D6
    Pierre Vandel
    Service de Psychiatrie et Psychologie médicale, Besancon, France
    World J Biol Psychiatry 4:74-80. 2003
    ....
  2. ncbi Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients
    P Vandel
    Fédération de Psychiatrie et Psychologie Médicale, Centre Hospitalo Universitaire, 25030 Besancon, France
    Hum Psychopharmacol 19:293-8. 2004
    ..Clinical implications and the possible connection between a decreased CYP2D6 activity and adverse drug effects were discussed. Caution should be taken when drugs with a low therapeutic index must be coprescribed in such patients...
  3. ncbi Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism
    P Vandel
    Service de Psychiatrie et Psychologie médicale, CHU 25030 Besançon, France
    Curr Pharm Des 13:241-50. 2007
    ..The aim of our review is to promote the application of pharmacogenetics in everyday clinical practice...
  4. ncbi Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
    P Vandel
    Hospitalo University Department of Psychiatry and Medical Psychology, Centre Hospitalo Universitaire, Besancon, France
    Eur J Clin Pharmacol 55:659-65. 1999
    ..The present study investigates whether patients who have developed and those who have not developed extrapyramidal drug side effects differ in their CYP2D6 genotypes and phenotypes...
  5. ncbi Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study
    Lina Steinacher
    Praxis am Zweierplatz, Badenerstrasse 67, CH-8004 Zurich, Switzerland
    Eur Neuropsychopharmacol 12:255-60. 2002
    ....
  6. ncbi A comparative study of milnacipran and paroxetine in outpatients with major depression
    Daniel Sechter
    Service de psychiatrie de l adulte, Centre Hospitalier Universitaire St Jacques, Besancon, Cedex F 25030, France
    J Affect Disord 83:233-6. 2004
    ..Milnacipran is a dual-action antidepressant which inhibits both serotonin and noradrenaline reuptake with no affinity for any neurotransmitter receptor studied...
  7. ncbi Odor perception in patients with mood disorders
    Sandrine Lombion-Pouthier
    Laboratoire de Neurosciences, Place Leclerc, , , France
    J Affect Disord 90:187-91. 2006
    ....